Ima is the first specific inhibitor of the BCR-ABL tyrosine kinase, and has revolutionized the treatment of CML, although DR is becoming a major problem [25]. The gene discussed is BCR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.